Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
Clinical trial NCT05401786 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05401786
- Sponsor
- The Netherlands Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-03
- Primary completion
- 2024-11-15
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.